Loading people...
Justin Hanes is a Venture Partner at Catalio Capital Management and the Director of the Center for Nanomedicine at Johns Hopkins University in Baltimore, Maryland. He holds a bachelor's degree from the University of California, Los Angeles, and a doctorate in chemical engineering from the Massachusetts Institute of Technology, where he was mentored by biotech pioneer Robert Langer. As a serial entrepreneur, Hanes has translated his laboratory research into multiple clinical-stage therapeutics companies, co-founding ventures such as Kala Pharmaceuticals and Graybug Vision, which completed its initial public offering in 2020. His previous entrepreneurial exits include the acquisition of Advanced Inhalation Research by Alkermes, and he currently holds more than 150 patents alongside hundreds of peer-reviewed scientific publications. Hanes focuses his ongoing academic research and venture capital investments on advancing targeted drug delivery systems and nanomedicine technologies.
Justin Hanes is a distinguished Venture Partner at Catalio Capital, a prominent investment firm renowned for its focus on the healthcare and life sciences sectors. In his pivotal role, Mr. Hanes is instrumental in identifying, evaluating, and nurturing groundbreaking companies that are poised to revolutionize patient care and medical innovation. He brings a strategic vision and deep industry acumen to Catalio's investment process, contributing significantly to the firm's mission of backing transformative technologies and businesses.
Mr. Hanes' investment focus aligns seamlessly with Catalio Capital's core expertise, spanning a broad spectrum of healthcare sub-sectors. This includes cutting-edge biotechnology, advanced medical devices, innovative diagnostics, and disruptive digital health solutions. He is particularly passionate about companies that leverage scientific breakthroughs and technological advancements to address unmet medical needs, improve healthcare delivery, and enhance patient outcomes. His work involves rigorous due diligence, strategic partnership development, and providing hands-on support to portfolio companies, guiding them through critical growth stages.
Before joining Catalio Capital, Justin Hanes cultivated a robust career within the healthcare and venture capital landscape. He brings a wealth of experience from various facets of the healthcare ecosystem, including prior roles in venture capital and strategic advisory capacities where he honed his expertise in market analysis, deal sourcing, and portfolio management. This diverse background has equipped him with a comprehensive understanding of the challenges and opportunities inherent in scaling innovative healthcare enterprises. His ability to identify high-potential ventures and provide invaluable strategic guidance has been a hallmark of his professional journey.
While specific individual investments are often a collaborative effort within a firm, Mr. Hanes plays a crucial role in shaping Catalio Capital's portfolio. He is actively involved in sourcing new opportunities, assessing their commercial viability and scientific merit, and working closely with founders and management teams to accelerate their development. His contributions help ensure that Catalio continues to invest in companies that not only promise significant financial returns but also deliver meaningful impact on global health. Justin Hanes embodies Catalio Capital's commitment to fostering innovation and driving progress in the ever-evolving healthcare industry.
Justin Hanes is a Venture Partner at Catalio Capital, a leading investment firm focused on healthcare and life sciences. He specializes in identifying and supporting innovative companies in biotechnology, medical devices, and digital health.
Justin Hanes invests in companies across the healthcare and life sciences sectors. His focus areas include biotechnology, medical devices, diagnostics, and digital health solutions, aligning with Catalio Capital's expertise in transformative healthcare technologies.
Justin Hanes works as a Venture Partner at Catalio Capital, a prominent investment firm dedicated to advancing innovation within the healthcare and life sciences industries.
